237 related articles for article (PubMed ID: 26970981)
1. Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma.
Rhome R; Fisher R; Hormigo A; Parikh RR
J Neurooncol; 2016 Jun; 128(2):241-50. PubMed ID: 26970981
[TBL] [Abstract][Full Text] [Related]
2. Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.
Kim YH; Kim T; Joo JD; Han JH; Kim YJ; Kim IA; Yun CH; Kim CY
Cancer; 2015 Sep; 121(17):2926-32. PubMed ID: 25975354
[TBL] [Abstract][Full Text] [Related]
3. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
4. Disparities in health care determine prognosis in newly diagnosed glioblastoma.
Chandra A; Rick JW; Dalle Ore C; Lau D; Nguyen AT; Carrera D; Bonte A; Molinaro AM; Theodosopoulos PV; McDermott MW; Berger MS; Aghi MK
Neurosurg Focus; 2018 Jun; 44(6):E16. PubMed ID: 29852776
[TBL] [Abstract][Full Text] [Related]
5. Concurrent chemoradiotherapy versus radiotherapy alone for "biopsy-only" glioblastoma multiforme.
Kole AJ; Park HS; Yeboa DN; Rutter CE; Corso CD; Aneja S; Lester-Coll NH; Mancini BR; Knisely JP; Yu JB
Cancer; 2016 Aug; 122(15):2364-70. PubMed ID: 27172136
[TBL] [Abstract][Full Text] [Related]
6. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
7. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
8. Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base.
Huang J; Samson P; Perkins SM; Ansstas G; Chheda MG; DeWees TA; Tsien CI; Robinson CG; Campian JL
J Neurooncol; 2017 Feb; 131(3):593-601. PubMed ID: 27844308
[TBL] [Abstract][Full Text] [Related]
9. Patterns of care and outcomes for glioblastoma in patients with poor performance status.
Malakhov N; Lee A; Garay E; Becker DJ; Schreiber D
J Clin Neurosci; 2018 Jun; 52():66-70. PubMed ID: 29576419
[TBL] [Abstract][Full Text] [Related]
10. Patterns of care and outcomes of multi-agent versus single-agent chemotherapy as part of multimodal management of low grade glioma.
Haque W; Verma V; Butler EB; Teh BS
J Neurooncol; 2017 Jun; 133(2):369-375. PubMed ID: 28432588
[TBL] [Abstract][Full Text] [Related]
11. Addition of chemotherapy to hypofractionated radiotherapy for glioblastoma: practice patterns, outcomes, and predictors of survival.
Haque W; Verma V; Butler EB; Teh BS
J Neurooncol; 2018 Jan; 136(2):307-315. PubMed ID: 29090416
[TBL] [Abstract][Full Text] [Related]
12. Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma.
Jain V; Venigalla S; Sebro RA; Karakousis GC; Wilson RJ; Weber KL; Shabason JE
Cancer Med; 2019 Oct; 8(14):6295-6304. PubMed ID: 31483578
[TBL] [Abstract][Full Text] [Related]
13. Association of race and health insurance in treatment disparities of colon cancer: A retrospective analysis utilizing a national population database in the United States.
Hao S; Snyder RA; Irish W; Parikh AA
PLoS Med; 2021 Oct; 18(10):e1003842. PubMed ID: 34695123
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma multiforme (GBM) in the elderly: initial treatment strategy and overall survival.
Glaser SM; Dohopolski MJ; Balasubramani GK; Flickinger JC; Beriwal S
J Neurooncol; 2017 Aug; 134(1):107-118. PubMed ID: 28527010
[TBL] [Abstract][Full Text] [Related]
15. Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis.
Wen J; Chen W; Zhu Y; Zhang P
BMC Cancer; 2021 Jan; 21(1):81. PubMed ID: 33468109
[TBL] [Abstract][Full Text] [Related]
16. Patterns of care and predictors of adjuvant therapies in elderly patients with glioblastoma: An analysis of the National Cancer Data Base.
Amsbaugh MJ; Yusuf MB; Gaskins J; Burton EC; Woo SY
Cancer; 2017 Sep; 123(17):3277-3284. PubMed ID: 28452053
[TBL] [Abstract][Full Text] [Related]
17. Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients.
Behm T; Horowski A; Schneider S; Bock HC; Mielke D; Rohde V; Stockhammer F
Clin Neurol Neurosurg; 2013 Oct; 115(10):2142-6. PubMed ID: 23993314
[TBL] [Abstract][Full Text] [Related]
18. Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma.
Sun MZ; Oh T; Ivan ME; Clark AJ; Safaee M; Sayegh ET; Kaur G; Parsa AT; Bloch O
J Neurosurg; 2015 May; 122(5):1144-50. PubMed ID: 25768833
[TBL] [Abstract][Full Text] [Related]
19. EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.
Cominelli M; Grisanti S; Mazzoleni S; Branca C; Buttolo L; Furlan D; Liserre B; Bonetti MF; Medicina D; Pellegrini V; Buglione M; Liserre R; Pellegatta S; Finocchiaro G; Dalerba P; Facchetti F; Pizzi M; Galli R; Poliani PL
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25739547
[TBL] [Abstract][Full Text] [Related]
20. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
